Baseline characteristics of 29 patients who received both blinatumomab and inotuzumab ozogamicin for R/R precursor R/R as a whole cohort and as stratified according to the sequence of blinatumomab and inotuzumab ozogamicin
| Characteristic . | All patients (N = 29) . | Blinatumomab mAb1 (n = 25) . | Inotuzumab mAb1 (n = 4) . |
|---|---|---|---|
| Median age at diagnosis (IQR, y) | 45.3 (25.1-62.6) | 43.6 (24.4-60.7) | 61.2 (54.6-70.6) |
| Male sex | 17 (58.6) | 13 (52.0) | 4 (100.0) |
| Cytogenetic stratification* | |||
| High risk | 12 (41.4) | 10 (40.0) | 2 (50.0) |
| Standard risk | 14 (48.3) | 12 (48.0) | 2 (50.0) |
| Missing data | 3 (10.3) | 3 (12.0) | 0 (0.0) |
| Philadelphia chromosome–positive B-ALL | 4 (13.8) | 4 (16.0) | 0 (0.0) |
| Presence of extramedullary disease | 8 (27.6) | 6 (24.0) | 2 (50.0) |
| Complete response to first-line induction therapy | |||
| Relapse after achieving CR | 24 (82.8) | 22 (88.0) | 2 (50.0) |
| Refractory | 5 (17.2) | 3 (12.0) | 2 (50.0) |
| Median no. of prior treatment lines before first mAb (range, lines) | 1 (1-5) | 1 (1-5) | 1 (1-2) |
| Prior alloHSCT before mAb1 | 3 (10.3) | 3 (12.0) | 0 (0.0) |
| Prior CD19 CAR T-cell therapy before mAb1 | 3 (10.3) | 3 (12.0) | 0 (0.0) |
| Median bone marrow blast percentage at mAb1 (IQR, %) | 9 (3-25) | 9 (3-20) | 25 (14-58) |
| MRD at the time of mAb1 | 7 (24.1) | 7 (28.0) | 0 (0.0) |
| Median time from mAb1 to mAb2 (IQR, d) | 99 (35-240) | 99 (35-240) | 116 (55-221) |
| Received interim treatment between 2 mAbs | 14 (48.3) | 13 (52.0) | 1 (25.0) |
| Median number of blinatumomab cycles (range, cycles) | 1 (1-6) | 1 (1-6) | 2 (1-5) |
| Median number of inotuzumab cycles (range, cycles) | 2 (1-5) | 2 (1-5) | 2 (1-2) |
| alloHSCT after mAb2 | 12 (41.4) | 11 (44.0) | 1 (25.0) |
| Characteristic . | All patients (N = 29) . | Blinatumomab mAb1 (n = 25) . | Inotuzumab mAb1 (n = 4) . |
|---|---|---|---|
| Median age at diagnosis (IQR, y) | 45.3 (25.1-62.6) | 43.6 (24.4-60.7) | 61.2 (54.6-70.6) |
| Male sex | 17 (58.6) | 13 (52.0) | 4 (100.0) |
| Cytogenetic stratification* | |||
| High risk | 12 (41.4) | 10 (40.0) | 2 (50.0) |
| Standard risk | 14 (48.3) | 12 (48.0) | 2 (50.0) |
| Missing data | 3 (10.3) | 3 (12.0) | 0 (0.0) |
| Philadelphia chromosome–positive B-ALL | 4 (13.8) | 4 (16.0) | 0 (0.0) |
| Presence of extramedullary disease | 8 (27.6) | 6 (24.0) | 2 (50.0) |
| Complete response to first-line induction therapy | |||
| Relapse after achieving CR | 24 (82.8) | 22 (88.0) | 2 (50.0) |
| Refractory | 5 (17.2) | 3 (12.0) | 2 (50.0) |
| Median no. of prior treatment lines before first mAb (range, lines) | 1 (1-5) | 1 (1-5) | 1 (1-2) |
| Prior alloHSCT before mAb1 | 3 (10.3) | 3 (12.0) | 0 (0.0) |
| Prior CD19 CAR T-cell therapy before mAb1 | 3 (10.3) | 3 (12.0) | 0 (0.0) |
| Median bone marrow blast percentage at mAb1 (IQR, %) | 9 (3-25) | 9 (3-20) | 25 (14-58) |
| MRD at the time of mAb1 | 7 (24.1) | 7 (28.0) | 0 (0.0) |
| Median time from mAb1 to mAb2 (IQR, d) | 99 (35-240) | 99 (35-240) | 116 (55-221) |
| Received interim treatment between 2 mAbs | 14 (48.3) | 13 (52.0) | 1 (25.0) |
| Median number of blinatumomab cycles (range, cycles) | 1 (1-6) | 1 (1-6) | 2 (1-5) |
| Median number of inotuzumab cycles (range, cycles) | 2 (1-5) | 2 (1-5) | 2 (1-2) |
| alloHSCT after mAb2 | 12 (41.4) | 11 (44.0) | 1 (25.0) |
Data are presented as no. (%) unless otherwise indicated.
Based on UKALLXII/ECOG2993.2